Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses high glucose-induced proliferation and collagen synthesis in rat cardiac fibroblasts

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 6, 2011, Pages 387-394

  Zhou, Hong ^a   Zhang, Kai Xia ^a   Li, Yong Jun ^a   Guo, Bing Yan ^a   Wang, Mei ^a   Wang, Mian ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

C Jun N terminal kinase; Fasudil; Fibrosis; Rho kinase; Transforming growth factor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COLLAGEN TYPE 1; FASUDIL; GLUCOSE; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; PROCOLLAGEN; PROTEIN C JUN; RHO KINASE INHIBITOR; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; DIABETES MELLITUS; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE FIBROSIS; HYPERGLYCEMIA; IMMUNOCYTOCHEMISTRY; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GLUCOSE; MYOCARDIUM; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES;

EID: 79956331656     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05523.x     Document Type: Article

References (50)

1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
2. Van Heerebeek L, Hamdani N, Handoko ML et al. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117: 43-51.
3. Suskin N, McKelvie RS, Burns RJ et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur. Heart J. 2000; 21: 1368-75.
4. Jin D, Takai S, Sugiyama T et al. Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. J. Pharmacol. Sci. 2009; 109: 275-84.
5. Asbun J, Manso AM, Villarreal FJ. Profibrotic influence of high glucose concentration on cardiac fibroblast functions: Effects of losartan and vitamin E. Am. J. Physiol. Heart Circ. Physiol. 2005; 288: H227-34.
6. Tokudome T, Horio T, Yoshihara F et al. Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. Metabolism 2004; 53: 710-5.
7. Wang P, Li HW, Wang YP, Chen H, Zhang P. Effects of recombinant human relax upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition. J. Endocrinol. Invest. 2009; 32: 242-7.
8. Riento K, Ridley AJ. Rocks: Multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 2003; 4: 446-56.
9. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ. Res. 2005; 97: 1232-5.
10. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38: 1307-10.
11. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E, Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 2005; 238: 31-9.
12. Masumoto A, Mohri M, Shimokawa H et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105: 1545-7.
13. Kikuchi Y, Yamada M, Imakiire T et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol. 2007; 192: 595-603.
14. Peng FF, Wu DC, Gao B et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008; 57: 1683-92.
15. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-23.
16. Lin G, Craig GP, Zhang L et al. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc. Res. 2007; 75: 51-8.
17. Chen X, Tian Y, Yao L, Zhang J, Liu Y. Hypoxia stimulates proliferation of rat neural stem cells with influence on the expression of cyclin D1 and c-Jun N-terminal protein kinase signaling pathway in vitro. Neuroscience 2010; 165: 705-14.
18. Zhou CH, Wu XH, Wu YQ. Nobiletin, a dietary phytochemical, inhibits vascular smooth muscle cells proliferation via calcium-mediated c-Jun N-terminal kinases pathway. Eur. J. Pharmacol. 2009; 615: 55-60.
19. Hao GH, Niu XL, Gao DF, Wei J, Wang NP. Agonists at PPAR-γ suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br. J. Pharmacol. 2008; 153: 1409-19.
20. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: Implications for ventricular remodelling. Clin. Exp. Pharmacol. Physiol. 2005; 32: 697-701.
21. Martin J, Kelly DJ, Mifsud SA et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: Role of transforming growth factorâ. Cardiovasc. Res. 2005; 65: 694-701.
22. Kim NN, Villarreal FJ, Printz MP, Lee AA, Dillmann WH. Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Am. J. Physiol. 1995; 269: E426-37.
23. Freedman LJ, Maddox MT. A comparison of anti-biotin and biotinylated anti-avidin double-bridge and biotinylated tyramide immunohistochemical amplification. J. Neurosci. Methods 2001; 112(1): 43-9.
24. Wakino S, Hayashi K, Kanda T et al. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ. Res. 2004; 95: E45-55.
25. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J. Cell Sci. 2004; 117: 4619-28.
26. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005; 65: 40-51.
27. Khan R, Sheppard R. Fibrosis in heart disease. Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118: 10-24.
28. Mizushige K, Yao L, Noma T et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
29. Tang M, Zhang W, Lin H, Jiang H, Dai H, Zhang Y. High glucose promotes the production of collagen type I and III by cardiac fibroblasts through a pathway dependent on extracellular-signal-regulated kinase 1/2. Mol. Cell. Biochem. 2007; 301: 109-14.
30. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: Role in extracellular matrix production. Am. J. Physiol. Heart Circ. Physiol. 2008; 294: H1675-84.
31. Phrommintikul A, Tran L, Kompa A et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008; 294: H1804-14.
32. Fukushima M, Nakamuta M, Kohjima M et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2005; 25: 829-38.
33. Chen XY, Dun JN, Miao QF, Zhang YJ. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 2009; 83: 67-79.
34. +/- haploinsufficient mice. Circulation 2005; 112: 2959-65.
35. Rikitake Y, Kim HH, Huang Z et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36: 2251-7.
36. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005; 111: 3261-8.
37. Papakrivopoulou J, Lindahl GE, Bishop JE, Laurent GJ. Differential roles of extracellular signal-regulated kinase 1/2 and p38MAPK in mechanical load-induced procollagen alpha1(I) gene expression in cardiac fibroblasts. Cardiovasc. Res. 2004; 61: 736-44.
38. Chuang LY, Guh JY, Chen YW, Wang KA, Huang YJ, Huang JS. Role of nitric oxide in high glucose-induced mitogenic response in renal fibroblasts. Mol. Endocrinol. 2006; 20: 2548-58.
39. Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells to high glucose environments activates the P38MAPK pathway. Kidney Int. 2001; 60: 858-71.
40. He XQ, Chen R, Yang P, Li AP, Zhou JW, Liu QZ. Biphasic effect of arsenite on cell proliferation and apoptosis is associated with the activation of JNK and ERK1/2 in human embryo lung fibroblast cells. Toxicol. Appl. Pharmacol. 2007; 220: 18-24.
41. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol. Cell 2004; 14: 29-41.
42. Ouwens DM, Gomes de Mesquita DS, Dekker J, Maassen JA. Hyperosmotic stress activates the insulin receptor in CHO cells. Biochim. Biophys. Acta 2001; 1540: 97-106.
43. Thirone AC, Speight P, Zulys M et al. Hyperosmotic stress induces Rho/Rho kinase/LIM kinase-mediated cofilin phosphorylation in tubular cells: Key role in the osmotically triggered F-actin response. Am. J. Physiol. Cell Physiol. 2009; 296: C463-75.
44. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J. Am. Soc. Nephrol. 2006; 17: 2193-201.
45. Nagatoya K, Moriyama T, Kawada N et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2002; 61: 1684-95.
46. Nishikimi T, Akimoto K, Wang X et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J. Hypertens. 2004; 22: 1787-96.
47. Gojo A, Utsunomiya K, Taniguchi K et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2007; 568: 242-7.
48. Kishi T, Hirooka Y, Masumoto A et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005; 111: 2741-7.
49. Zeng L, Xu H, Chew TL et al. HMG-CoA reductase inhibitor modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J. 2005; 19: 1845-7.
50. Xu H, Zeng L, Peng H et al. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced 'inside-out' signailing to extracellular matrix by preventing RhoA activation. Am. J. Physiol. Renal Physiol. 2006; 291: F995-1004.